Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

In a report released today, Sachin Jain from Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price target of DKK350.00....

Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novo Nordisk today and set a price target of DKK290.00. According to TipRanks,...

Deutsche Bank  Remains a Hold on Novo Nordisk (0QIU)

Barclays analyst James Gordon CFA maintained a Hold rating on Novo Nordisk today and set a price target of DKK310.00. According to TipRanks, Gordon...

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

The company beat Wall Street forecasts across the board. 


Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside

UBS analyst Matthew Weston maintained a Hold rating on Novo Nordisk today and set a price target of DKK332.00. According to TipRanks, Weston is ran...

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Novo Nordisk ( ($NVO) ) has issued an update. Novo Nordisk reported its adjusted financial performance for the second quarter of 2026 on 4 August 2...

Novo Nordisk Lifts 2026 Outlook After Strong Q2 Adjusted Results

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S is running a real‑world database study called “Database L...

Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users

An announcement from Novo Nordisk ( ($NVO) ) is now available. Novo Nordisk A/S reported progress on its previously announced share repurchase prog...

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Novo Nordisk ($NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed a major Phase 3 c...

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK250.00. According to TipRanks, Vosse...

J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The ZEUS trial, officially titled “ZEUS – Effects of Ziltivekimab Versus P...

Novo Nordisk’s ZEUS Trial Reaches Completion: What It Could Mean for NVO Investors

The two companies dominate the market for obesity medications. 


Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

The new medication helps people who also have diabetes and cardiovascular disease. 


Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The AMAZE 13 study, formally titled “Efficacy and Safety of Zenagamtide s....

Novo Nordisk’s AMAZE 13 Trial Adds Fresh Momentum to Its Obesity Pipeline

Novo Nordisk ( ($NVO) ) has shared an announcement. On 6 May 2026, Novo Nordisk A/S launched a share repurchase programme under EU Safe Harbour rul...

Novo Nordisk Ramps Up DKK 15 Billion Share Buyback Programme

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00. Accor...

Novo Nordisk (0QIU) Receives a Hold from Deutsche Bank

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The phase 3 study “Efficacy and Safety of Co-administered Cagrilintide and...

Novo Nordisk’s CagriSema Trial Wraps Up: What Completed Phase 3 Data Could Mean for NVO

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S is running a large Phase 3 study called “Efficacy and Saf...

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The Phase 2 study Efficacy and Safety of Once-weekly Subcutaneous UBT251 i...

Novo Nordisk’s New Diabetes Bet: What the UBT251 Trial Could Mean for NVO Investors

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK332.00. According to TipRan...

Novo Nordisk (0QIU) Receives a Hold from UBS

Novo Nordisk A/S ($NVO), a global healthcare company best known for its diabetes and obesity treatments, reported new phase 3 data that could stren...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$47.26	+2.81%	12.08M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$47.26	+2.8%	12.08M
3
4
5
6

NVO

NVO

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel